stockrow
Monday 9 November 2026
Export ORMP’s income statement to Excel — free account
Oramed Pharmaceuticals Inc.
ORMPOramed Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, up 49.3% from fiscal 2023.
- Revenue
- +193.3%
- EPS
- +493.8%
- Free cash flow
- +94.3%
Quarter to June 2026, against a year earlier
3.86
0.03
−0.77%
Follow ORMP
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
24.51% | 36.65% | 57.75% | 73.90% | |
| 22.75% | 32.76% | 52.45% | 65.52% | ||
ROIC |
(12.02%) | (12.77%) | (5.16%) | (3.40%) | |
Return on Tangible Assets |
33.57% | 55.10% | 187.79% | 402.85% | |
Average Days of Receivables |
— | — | — | 0.00 | |
Free Cash Flow per Share |
(0.25) | (0.22) | (0.21) | (0.13) | |
Free Cash Flow |
(10.61) | (9.15) | (8.55) | (5.21) | |
Capital Expenditures |
(0.02) | (0.01) | (0.01) | (0.01) | |
| Other line items | |||||
Cash ROIC |
(3.15%) | (2.81%) | (2.81%) | (1.42%) | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.21) | (0.15) | (0.17) | (0.21) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
(0.24) | (0.14) | (0.08) | (0.03) | |
Depreciation/Fixed assets |
0.20 | 0.21 | 0.22 | 0.23 | |
Capex/Depreciation |
(0.15) | (0.07) | (0.09) | (0.07) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.25) | (0.22) | (0.21) | (0.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026